For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

Read more

For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

Read more

We are committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

CEO David Veitch | Half-year 2020 Update

Play

News

 

In some countries, in particular in the United States, applicable laws may restrict or prohibit a public distribution of information contained in the following websites. Therefore, please provide the following information:

I am a Swiss resident*:
 

I am currently in Switzerland*:
 

Continue

* The information you provide will only be used for validation purposes and will not be provided to third parties.

 

In some countries, in particular in the United States, applicable laws may restrict or prohibit a public distribution of information contained in the following websites. Therefore, please provide the following information:

I am a Swiss resident*:
 

I am currently in Switzerland*:
 

Continue

* The information you provide will only be used for validation purposes and will not be provided to third parties.

CEO Statement

For the benefit of patients around the world, we are continuing to establish Cresemba and Zevtera as truly global brands. In addition, by strengthening our pre-clinical and clinical oncology pipeline, we aim to become a leading provider of innovative cancer therapies in the future.

Facts & Figures

Located in the heart of the life-sciences hub Basel

Play